Research Analysts’ upgrades for Wednesday, August 16th:
Celgene Corporation (NASDAQ:CELG) was upgraded by analysts at Vetr from a buy rating to a strong-buy rating. The firm currently has $148.32 target price on the stock.
Fitbit (NYSE:FIT) was upgraded by analysts at Vetr from a hold rating to a buy rating. The firm currently has $5.79 price target on the stock.
Medical Transcription Billing, Corp. (NASDAQ:MTBC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.50 target price on the stock. According to Zacks, “Medical Transcription Billing, Corp. is a healthcare information technology company. It engages in providing integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company offers revenue cycle, practice management services, patient scheduling, automated appointment reminders, e-prescribing, lab connectivity, and real-time insurance eligibility verification. Transcription Billing, Corp. is headquartered in Somerset, New Jersey. “
Mitsubishi Chem Hl (NASDAQ:MTLHY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Mitsubishi Chemical Holdings Corporation engages in the production and sale of various chemical, healthcare, and performance products primarily in Japan. The company’s Electronics Applications segment offers optical recording media, display materials, and polyester films. Its Designed Materials segment engages in the business related to aluminum composite materials, sales of construction and industrial materials, plastic shrinkable labels for PET bottles and heat shrinkable tubes. The company’s Health Care segment is involved in businesses related to chemicals and related products, manufacture and sale of pharmaceuticals, clinical testing and diagnostics. Its Chemicals segment engages in the businesses of industrial and specialty chemicals, nonionic surfactants, glycol ethers, and fine chemicals. The company’s Polymers segment’s businesses comprise activities in the areas of PET, polyethylene, and nylon resins for automotive industry. Mitsubishi Chemical Holdings Corporation is headquartered in Tokyo, Japan. “
Nordic American Tankers Limited (NYSE:NAT) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “NORDIC AMERICAN is engaged of acquiring, disposing, owning, leasing, and chartering three double hull Suezmax oil tankers. “
NovaBay Pharmaceuticals (NYSE:NBY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. “
Novavax (NASDAQ:NVAX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $1.25 target price on the stock. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
Obalon Therptcs (NASDAQ:OBLN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company’s product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. “
AT&T (NYSE:T) was upgraded by analysts at Vetr from a buy rating to a strong-buy rating. They currently have $42.91 target price on the stock.
Under Armour (NYSE:UA) was upgraded by analysts at Vetr from a buy rating to a strong-buy rating. The firm currently has $18.82 price target on the stock.
